4 / 5
allied
academies
Page 17
Notes:
September 16-17, 2019 | Paris, France
Dementia and Alzheimer's Disease
13
th
World Congress on
Journal of Clinical Psychiatry and Cognitive Psychology | Volume: 03
Clinical characteristics and prognostic value of various Psychotic features in DLB patients
Elena Vasenina, Chimagomedova A, Anikina M
and
Levin O
Russian Medical Academy of Continuous Professional Education, Russia
D
ementia with Lewy bodies is the second most
prevalent
neurodegenerative
dementia
after
Alzheimer's Disease. Key attributes of DLB are
parkinsonism, visual hallucinations, attention fluctuations,
and RBD. Parkinsonism is represented by heterogeneous
feature set, however it has no particular specificity
besides having left-side onset more often and presence of
myoclonus which directly correlates to psychotic disorders.
Defining fluctuations as well as approaches to diagnostics
of them continues to be the topic of discussions, similar
phenomenon is also observed in different dementias which
also doesn't allow to treat it as a specific feature. Psychotic
disorders in DLB patients are various, most typical are
visual hallucinations, however illusions, passage and
presence phenomena, impaired identification as well as
other delusional disorders are observed. Based on analysis
of 148 DLB patients we have shown specific relations of
various psychotic symptoms with particular cognitive
domains and revealed sequence of their occurrence.
Using 1.5 Tesla MRI it was possible to reveal relations
between psychotic symptoms and damage of specific
structures. Analysis of particularities in neuropsychological
profile and particular pattern of damage shown by MRI
allowed to explain the "silence" of visual hallucinations
and rare occurrence of auditory hallucinations. Complex
approach allowed to differentiate between 3 DLB subtypes
considering period of psychotic disorders occurrence,
specifics thereof, cognitive impairments particularities
and neuroimaging data. The subtypes we identified show
differences in response to basic anti-dementia therapy
(cholinesterase inhibitors and Memantine), which allows
for differentiated approach to therapy and prognosis.
Speaker Biography
Elena Vasenina received her MD in 2009. At the age of 27 years she
has completed her PhD studies “Cholinesterase inhibitors in treatment
of DLB patients” from the Russian Medical Academy of Continuous
Professional Education, Russia. Now she is associate professor of
neurology department of the Russian Medical Academy of Continuous
Professional Education, Moscow, Russia. She has over 100 publications
that have been cited over 200 times.
e:
hel_vas@mail.ru